Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-03-23
|
Brilinta® (ticagrelor) |
prevention of major vascular events in patients with an acute ischaemic strok |
3 |
AstraZeneca (UK) |
Cardiovascular diseases |
2016-03-23
|
AGS-003 |
non-small cell lung cancer (NSCLC) |
2 |
Argos Therapeutics (USA - NC) |
Cancer - Oncology |
2016-03-22
|
CHIKV-dMAb |
chikungunya virus infection |
preclinical |
Inovio Pharmaceuticals (USA - PA) |
Infectious diseases |
2016-03-21
|
atezolizumab (MPDL3280A) and daratumumab |
multiple myeloma |
1b |
Genentech, a member of Roche Group (USA - CA - Switzerland) |
Cancer - Oncology |
2016-03-21
|
rigosertib |
myelodysplastic syndrome |
3 |
Onconova Therapeutics (USA - PA) |
Cancer - Oncology |
2016-03-19
|
PV-10 and pembrolizumab |
Stage III locally advanced cutaneous melanoma |
3 |
Provectus Pharmaceuticals (USA - TN) |
Cancer - Oncology |
2016-03-18
|
Remsima® (biosimilar infliximab) |
inflammatory bowel disease, Crohn’s disease, ulcerative colitis |
|
Celltrion Healthcare (South Korea) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-03-17
|
demcizumab and pembrolizumab |
locally advanced or metastatic solid tumors |
1b |
OncoMed Pharmaceuticals (USA - CA) Celgene (USA - NJ) |
Cancer - Oncology |
2016-03-17
|
MBX-8025 (2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate) |
homozygous familial hypercholesterolemia |
2 |
Cymabay Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Metabolic diseases |
2016-03-16
|
Livatag® (doxorubicin Transdrug®) |
hepatocellular carcinoma |
preclinical |
Onxeo (France) |
Cancer - Oncology - Rare diseases |
2016-03-16
|
gerilimzumab |
|
1 |
Bird Rock Bio, previously RuiYi (USA - CA) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-03-16
|
AGS-003 |
metastatic renal cell carcinoma |
3 |
Argos Therapeutics (USA - NC) |
Cancer - Oncology |
2016-03-16
|
oxyntomodulin (MOD-6031) |
obesity, type II diabetes |
1 |
Opko Health (USA - Fl) |
Metabolic diseases |
2016-03-16
|
VXM01 |
metastatic colorectal cancer |
1 |
Vaximm (Germany) |
Cancer - Oncology |
2016-03-16
|
pegylated recombinant human hyaluronidase - PEGPH20 In combination With Abraxane® (nab-paclitaxel) and gemcitabine |
pancreatic ductal adenocarcinoma |
3 |
Halozyme Therapeutics (USA - CA) |
Cancer - Oncology |
2016-03-16
|
Vx-001 |
non-small-cell lung cancer |
2b |
Vaxon Biotech (France) |
Cancer - Oncology |
2016-03-16
|
EBV-CTL (allogeneic Epstein-Barr virus cytotoxic T lymphocytes) |
EBV-associated nasopharyngeal carcinoma |
|
Atara Biotherapeutics (USA - CA) |
Cancer - Oncology |
2016-03-15
|
IMP321 |
melanoma |
1-2a |
Prima Biomed (Australia) |
Cancer - Oncology |
2016-03-15
|
PBI-4050 |
scleroderma |
2 |
ProMetic Life Sciences (Canada) |
Autoimmune diseases - Rheumatic diseases |
2016-03-14
|
yttrium-90- labeled (90Y) clivatuzumab tetraxetan |
metastatic pancreatic cancer |
3 |
Immunomedics (USA - NJ) |
Cancer - Oncology |